Recombinant Human LYPD3 (C-6His)

Description

EnkiLife provides the Recombinant Human LYPD3 (C-6His) protein,aslo know as Ly6/PLAUR Domain-Containing Protein 3,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,Matrigel-Induced Gene C4 Protein,MIG-C4,LYPD3,C4.4A, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Ly6/PLAUR Domain-Containing Protein 3 is produced by our Mammalian expression system and the target gene encoding Leu31-His286 is expressed with a 6His tag at the C-terminus.Accession:O95274. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:27.89 KDa. Background:Ly6/PLAUR domain containing3 (LYPD-3) is a GPI-linked protein. The structure of LYPD-3 is similar to the urokinasetype plasminogen activator receptor (uPAR). LYPD-3 is a 6 -100 kDa molecule with variable cell type-specific N-O-linked glycosylation, mature human LYPD-3 contains two uPAR/Ly6 domains and a Ser/Thr/Pro-rich (STP) region includes a protease sensitive site . The interaction of LYPD-3 with Laminin 1 and 5 on neighboring cells promotes the adhesion, spreading, and migration of tumor cells. LYPD-3 additionally interacts with Galectin-3 and the anterior gradient proteins AG-2 and AG-3. LYPD-3 overexpression in non-small cell lung cancer is predictive of increased mortality.